IPP Bureau
Lupin launches first generic version of Oracea in US
By IPP Bureau - April 10, 2024
Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients
Shivalik Rasayan’s API facility gets 7 observations from USFDA
By IPP Bureau - April 10, 2024
These observations are procedural in nature and will be responded within the stipulated time
President Murmu to inaugurate homeopathic symposium on World Homoeopathy Day 2024
By IPP Bureau - April 10, 2024
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
SPARC announces results from planned interim analysis of PROSEEK Study
By IPP Bureau - April 10, 2024
Eugia Steriles gets 3 observations from USFDA for injectable facility
By IPP Bureau - April 07, 2024
The observations are procedural in nature and will be responded to within the stipulated time
Bayer and Dr. Reddy's sign marketing and distribution agreement for second brand of Vericiguat in India
By IPP Bureau - April 07, 2024
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Gland Pharma receives USFDA approval for Eribulin Mesylate Injection
By IPP Bureau - April 07, 2024
The Product is expected to be the first generic approval on the market
Pluss unveils Celsure XL VIP pallets
By IPP Bureau - April 07, 2024
A game changing solution for the pharmaceutical industry
Wacker and Pantherna intensify collaboration in the development and production of mRNA biopharmaceuticals
By IPP Bureau - April 07, 2024
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
LANXESS showcases extensive portfolio for the cosmetics industry at in-cosmetics Global
By IPP Bureau - April 07, 2024
Highly effective preservation solutions ensuring the safety and protection of personal care products
.jpg "Cipla Patalganga facility gets 6 USFDA observations")
Cipla Patalganga facility gets 6 USFDA observations
By IPP Bureau - April 07, 2024
The regulator carried out a routine current Good Manufacturing Practices (cGMP) inspection from March 28 to April 4.
USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma
By IPP Bureau - April 06, 2024
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Enhertu approved in the US as first tumour-agnostic HER2-directed therapy
By IPP Bureau - April 06, 2024
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Imfinzi significantly improved overall survival and progression-free survival in ADRIATIC Phase III trial
By IPP Bureau - April 06, 2024
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
Pfizer’s Velsipity UK approval will raise competition in ulcerative colitis market, says GlobalData
By IPP Bureau - April 06, 2024
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
